IP Library › Granted Patent US 12,668,773
Granted Patent B2
US 12,668,773 · App. 17/783,598 · Granted Jun 30, 2026

Production method for organoid

Inventors: Kentaro Shoji (Tokyo, JP); Toshiro Sato (Tokyo, JP)
Assignees: JSR Corporation; KEIO UNIVERSITY
C12N5/06C07K14/4743C07K14/485C07K14/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,668,773
App. No.
17/783,598
Filed
Jun 8, 2022
Granted
Jun 30, 2026
Kind
B2
Art Unit
1634
USPC
435/325
Abstract

A production method for an organoid, the production method including a step of culturing adult stem cells or a cell tissue piece including adult stem cells in a medium containing a chimeric Fibroblast Growth Factor (FGF) that includes a partial region of FGF1 and a partial region of FGF2; an organoid produced by the production method; a medium including a chimeric FGF and having a content of chimeric FGF of 50 ng/mL or less; and an evaluation method for a test substance are provided, and according to the chimeric FGF, a content of growth factors included in a medium can be reduced.

Claims (25)

1 . A production method for an organoid, the method comprising:

culturing adult stem cells or a stem cell tissue piece including adult stem cells in a medium comprising a chimeric Fibroblast Growth Factor (FGF) having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

2 . The production method according to claim 1 ,

wherein a content of the chimeric FGF included in the medium is 50 ng/ml or less.

3 . The production method according to claim 1 ,

wherein the medium further comprises Epidermal Growth Factor (EGF).

4 . The production method according to claim 3 ,

wherein a total content of the chimeric FGF and the EGF included in the medium is 100 ng/ml or less.

5 . The production method according to claim 1 ,

wherein the medium further contains comprises an Insulin-like growth factor (IGF) signaling pathway promoter.

6 . The production method according to claim 1 ,

wherein the medium further comprises a Transforming Growth Factor-β (TGF-β) signaling pathway inhibitor.

7 . The production method according to claim 1 ,

wherein the medium further comprises a Wnt signaling pathway promoter.

8 . The production method according to claim 1 ,

wherein the medium further comprises a Rho-kinase (ROCK) signaling pathway inhibitor.

9 . The production method according to claim 1 ,

wherein the medium further comprises a Bone morphogenetic protein (BMP) signaling pathway inhibitor.

10 . A medium comprising a chimeric FGF,

wherein the chimeric FGF is a protein having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, and

wherein a content of the chimeric FGF is 50 ng/ml or less.

11 . The medium according to claim 10 ,

wherein the medium further comprises EGF, and a total content of the chimeric FGF and the EGF is 100 ng/ml or less.

12 . A chimeric FGF, wherein the chimeric FGF is a protein having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

13 . The production method according to claim 1 , wherein the adult stem cells are epithelial stem cells.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Mar 31, 2025
From: JSR CORPORATION; JICC-02 CO., LTD.
To: JSR CORPORATION
Reel/Frame 070675/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: SHOJI, KENTARO; SATO, TOSHIRO
To: JSR CORPORATION; KEIO UNIVERSITY
Reel/Frame 060142/0459 →
Priority Claims (1)
JP 2019-226710 · Dec 16, 2019 · national
Continuity (1)
Related Publication 20230002724A1 · Jan 5, 2023
References Cited (17)
US 20100286042A1 · Imamura · 2010 [cited by examiner]
US 20140256037A1 · Sato · 2014 [cited by examiner]
US 20150299280A1 · Nakayama et al. · 2015 [cited by applicant]
US 20190390171A1 · Sato et al. · 2019 [cited by applicant]
US 20200157507A1 · Matsunaga et al. · 2020 [cited by applicant]
EP 213296A1 · 2010 [cited by applicant]
EP 3460042A1 · 2019 [cited by applicant]
JP 2014100141A · 2014 [cited by applicant]
WO WO2009048119A1 · 2009 [cited by applicant]
WO WO2017199811A1 · 2017 [cited by applicant]
WO WO2018207714A1 · 2018 [cited by applicant]
International Search Report issued Mar. 2, 2021 in PCT/JP2020/046783 filed on Dec. 15, 2020, citing documents AA-AC, AP-AR and AY therein, 5 pages (with English Translation). [cited by applicant]
Huch, M. et al., “Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver”, Cell 160, pp. 299-312, 2015. [cited by applicant]
Huch, M. et al., “Modeling mouse and human development using organoid cultures”, Development, vol. 142, pp. 3113-3125, doi:10.1242/dev.118570, 2015. [cited by applicant]
Extended European Search Report issued Jan. 12, 2024 in European Patent Application No. 20901631.0, citing references 1 and 15-16 therein, 9 pages. [cited by applicant]
Combined Chinese Office Action and Search Report issued Jul. 30, 2023, in corresponding Chinese Patent Application No. 202080085820.9 (with English Translation) citing document 24 therein, 17 pages. [cited by applicant]
Masayuki Fujii et al., “Human intestinal organoids maintain self-renewal capacity and cellular diversity in niche-inspired culture condition”, Cell Stem Cell, vol. 23, 787-793, pp. e1-e6. [cited by applicant]